Key Points - Pharmaceutical giant Eli Lilly's product lineup is just looking too good to pass up. - Drugs for obesity and diabetes, along with a strong pipeline, make this a must-have stock. - If the company's own guidance holds true, its valuation still remains reasonable. It's not often that…
Continue reading...